Prednisone
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AstraZenecaSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Weill Medical College of Cornell University | Phase 2 | BBB |
Chlorambucil Ascentage Pharma Group Inc. | Phase 4 | BBB |
Lisaftoclax Henan Cancer Hospital | Phase 3 | BBB |
Irinotecan IGM Biosciences, Inc. | Phase 2 | BBB |
Alvocidib Sanofi | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Prednisone is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →